Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBITDA (2020 - 2025)

Historic EBITDA for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.7 million.

  • Rhythm Pharmaceuticals' EBITDA fell 1997.95% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 2986.91%. This contributed to the annual value of -$265.5 million for FY2024, which is 4401.57% down from last year.
  • Rhythm Pharmaceuticals' EBITDA amounted to -$52.7 million in Q3 2025, which was down 1997.95% from -$45.3 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' EBITDA's 5-year high stood at -$34.4 million during Q1 2021, with a 5-year trough of -$139.9 million in Q1 2024.
  • Moreover, its 5-year median value for EBITDA was -$44.2 million (2021), whereas its average is -$49.7 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' EBITDA plummeted by 16629.42% in 2024, and later soared by 6639.86% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' EBITDA (Quarter) stood at -$51.0 million in 2021, then rose by 17.43% to -$42.1 million in 2022, then grew by 1.99% to -$41.3 million in 2023, then rose by 0.02% to -$41.3 million in 2024, then decreased by 27.63% to -$52.7 million in 2025.
  • Its last three reported values are -$52.7 million in Q3 2025, -$45.3 million for Q2 2025, and -$47.0 million during Q1 2025.